Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

Tech entrepreneur and longevity advocate Bryan Johnson has discontinued his use of rapamycin, a controversial anti-ageing ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, finds itself at a critical juncture as it navigates a complex landscape of opportunities and challenges. The company's recent performance and ...

An estimated 21 million American adults suffer from clinical depression. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...

We recently published a list of 12 Safe Stocks to Buy for the Long Term in 2025. In this article, we are going to take a look ...

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the FDA has blessed the nasal spray to be used as a monotherapy for major ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company ...